JP2016514148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514148A5 JP2016514148A5 JP2016501850A JP2016501850A JP2016514148A5 JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5 JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778540P | 2013-03-13 | 2013-03-13 | |
| US61/778,540 | 2013-03-13 | ||
| US201361808381P | 2013-04-04 | 2013-04-04 | |
| US61/808,381 | 2013-04-04 | ||
| PCT/US2014/025441 WO2014159911A1 (en) | 2013-03-13 | 2014-03-13 | Compositions comprising anti-cd38 antibodies and carfilzomib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514148A JP2016514148A (ja) | 2016-05-19 |
| JP2016514148A5 true JP2016514148A5 (https=) | 2017-06-15 |
| JP6279065B2 JP6279065B2 (ja) | 2018-02-14 |
Family
ID=51625288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501850A Active JP6279065B2 (ja) | 2013-03-13 | 2014-03-13 | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160022813A1 (https=) |
| EP (2) | EP2968555B1 (https=) |
| JP (1) | JP6279065B2 (https=) |
| KR (2) | KR20210043006A (https=) |
| CN (3) | CN105407921A (https=) |
| AU (1) | AU2014244333B2 (https=) |
| CA (1) | CA2904630A1 (https=) |
| ES (1) | ES2808565T3 (https=) |
| IL (2) | IL292978A (https=) |
| MX (1) | MX373308B (https=) |
| MY (1) | MY175418A (https=) |
| PL (1) | PL2968555T3 (https=) |
| PT (1) | PT2968555T (https=) |
| RU (2) | RU2723937C2 (https=) |
| SG (3) | SG10201913777XA (https=) |
| WO (1) | WO2014159911A1 (https=) |
| ZA (1) | ZA201507310B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| MX368288B (es) | 2012-09-25 | 2019-09-27 | Morphosys Ag | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US20150118251A1 (en) * | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR20210030411A (ko) * | 2018-07-10 | 2021-03-17 | 사노피 | Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| CN115698065A (zh) * | 2019-12-06 | 2023-02-03 | 赛诺菲-安万特美国有限责任公司 | 艾萨妥昔单抗用于治疗复发性和/或难治性多发性骨髓瘤的用途 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20070042436A1 (en) * | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| RU2402568C2 (ru) * | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| US8129346B2 (en) | 2004-04-15 | 2012-03-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| PT2260835E (pt) | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
| ES2498794T3 (es) * | 2005-02-18 | 2014-09-25 | Medarex, L.L.C. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo |
| CA2625681C (en) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| CN101534860B (zh) * | 2006-08-07 | 2013-03-27 | 艾伯特生物治疗学公司 | 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法 |
| AU2007296259A1 (en) | 2006-09-15 | 2008-03-20 | Janssen Pharmaceutica Nv | Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
| WO2008037257A2 (en) * | 2006-09-26 | 2008-04-03 | Genmab A/S | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| MX338397B (es) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| CA2727278A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| EP3090737A1 (en) * | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| KR20160091440A (ko) * | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| DK2621531T3 (en) | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US9272014B2 (en) * | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| ES2825625T3 (es) | 2013-10-31 | 2021-05-17 | Sanofi Sa | Anticuerpos anti-CD38 específicos para tratar cánceres humanos |
| US20150118251A1 (en) | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| JP7712206B2 (ja) | 2019-01-28 | 2025-07-23 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置方法 |
| IL302640A (en) | 2020-11-03 | 2023-07-01 | Sanofi Aventis Us Llc | Use of isatuximab for the treatment of multiple myeloma |
| KR20250029015A (ko) | 2022-03-07 | 2025-03-04 | 사노피-아벤티스 유.에스. 엘엘씨 | 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도 |
-
2014
- 2014-03-13 SG SG10201913777XA patent/SG10201913777XA/en unknown
- 2014-03-13 MY MYPI2015702949A patent/MY175418A/en unknown
- 2014-03-13 IL IL292978A patent/IL292978A/en unknown
- 2014-03-13 KR KR1020217010487A patent/KR20210043006A/ko not_active Ceased
- 2014-03-13 ES ES14773270T patent/ES2808565T3/es active Active
- 2014-03-13 US US14/775,641 patent/US20160022813A1/en not_active Abandoned
- 2014-03-13 MX MX2015012297A patent/MX373308B/es active IP Right Grant
- 2014-03-13 RU RU2018134595A patent/RU2723937C2/ru active
- 2014-03-13 EP EP14773270.5A patent/EP2968555B1/en active Active
- 2014-03-13 KR KR1020157027249A patent/KR102241868B1/ko active Active
- 2014-03-13 PT PT147732705T patent/PT2968555T/pt unknown
- 2014-03-13 PL PL14773270T patent/PL2968555T3/pl unknown
- 2014-03-13 CA CA2904630A patent/CA2904630A1/en not_active Abandoned
- 2014-03-13 SG SG11201506956TA patent/SG11201506956TA/en unknown
- 2014-03-13 CN CN201480024843.3A patent/CN105407921A/zh active Pending
- 2014-03-13 CN CN202510798995.9A patent/CN120860201A/zh active Pending
- 2014-03-13 RU RU2015143462A patent/RU2670127C2/ru active
- 2014-03-13 SG SG10201707464SA patent/SG10201707464SA/en unknown
- 2014-03-13 JP JP2016501850A patent/JP6279065B2/ja active Active
- 2014-03-13 WO PCT/US2014/025441 patent/WO2014159911A1/en not_active Ceased
- 2014-03-13 EP EP20180210.5A patent/EP3769783A1/en not_active Withdrawn
- 2014-03-13 AU AU2014244333A patent/AU2014244333B2/en active Active
- 2014-03-13 CN CN202010773679.3A patent/CN112043826A/zh active Pending
- 2014-03-13 IL IL241407A patent/IL241407B/en unknown
-
2015
- 2015-10-01 ZA ZA2015/07310A patent/ZA201507310B/en unknown
-
2016
- 2016-12-22 US US15/389,279 patent/US20170106085A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,693 patent/US20190321471A1/en not_active Abandoned
-
2021
- 2021-05-19 US US17/324,478 patent/US12533411B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514148A5 (https=) | ||
| JP2016506388A5 (https=) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2013542191A5 (https=) | ||
| JP2017048208A5 (https=) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| JP2021526136A5 (https=) | ||
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2016536314A5 (https=) | ||
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| EA201791186A1 (ru) | Антитела к cd38 | |
| HRP20191115T1 (hr) | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora | |
| JP2012136541A5 (https=) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015530399A5 (https=) | ||
| WO2016022589A3 (en) | Methods for treating multiple myeloma | |
| JP2010500370A5 (https=) | ||
| JP2020502198A5 (https=) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) |